Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients.

Trial Profile

Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Anti pseudomonas aeruginosa IgY (Primary)
  • Indications Pseudomonal infections
  • Focus Therapeutic Use
  • Acronyms IMPACTT-PsAer-IgY; PsAer-IgY
  • Most Recent Events

    • 03 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 05 Aug 2015 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top